Dynavax Technologies | DVAX - Current Assets

Stock Price
15.47
Daily Change
-0.02 -0.13%
Monthly
0.39%
Yearly
19.00%
Q1 Forecast
15.01

Dynavax Technologies reported $814.33M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
AbbVie USD 28.54B 722M Sep/2025
Adma Biologics USD 402.66M 3.1M Sep/2025
Amgen USD 27.88B 1.15B Sep/2025
AstraZeneca USD 29.94B 1B Sep/2025
Biogen USD 8.94B 968.9M Sep/2025
BioMarin Pharmaceutical USD 3.85B 49.21M Sep/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Dynavax Technologies USD 814.33M 28.62M Sep/2025
Gilead Sciences USD 18.84B 4.12B Sep/2025
Glaxosmithkline GBP 23.98B 6.31B Sep/2025
Merck USD 47.56B 10.49B Sep/2025
Neurocrine Biosciences USD 2.16B 409.5M Sep/2025
Novartis USD 28.2B 2.26B Sep/2025
Pfizer USD 46.92B 3.22B Sep/2025
Regeneron Pharmaceuticals USD 17.98B 1.12B Sep/2025
Roche Holding CHF 38.73B 3.03B Dec/2025
Sarepta Therapeutics USD 2.72B 65.32M Sep/2025
TG Therapeutics USD 599.76M 64.2M Sep/2025
Vertex Pharmaceuticals USD 10.57B 141.7M Sep/2025